本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为加大股东回报力度，分享经营成果，提振投资者持股信心，根 据《上市公司监管指引第 3 号——上市公司现金分红》、《上海证券交 易所股票上市规则》、《公司章程》相关规定，提请股东大会授权公司 董事会根据当期经营情况及未来可持续发展所需资金，在符合利润分 配的前提条件下，适时制定公司 2025 年中期（包含半年度、前三季 度）利润分配方案并实施，但中期分红上限不应超过相应期间归属于 上市公司股东的净利润。 山东省药用玻璃股份有限公司 关于提请股东大会授权董事会制定 2025 年中期利润分配预 案的公告 证券代码：600529 证券简称：山东药玻 编号：2025-017 本公告尚需提交公司 2024 年年度股东大会审议通过后方可实施， 敬请广大投资者注意投资风险。 特此公告。 山东省药用玻璃股份有限公司 董事会 2025 年 4 月 25 日 1 ...

证券代码：600529 证券简称：山东药玻 编号：2025-016 山东省药用玻璃股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ●主要内容： 公司拟以 2024 年末总股本 663,614,113 股为基数，向全体股东 每 10 股 派 发 现 金 3.20 元 （ 含 税 ）， 拟 分 配 现 金 股 利 共 计 212,356,516.16 元（含税）。 ●审议程序： 1 199,084,233.90 元，合计 411,440,750.06 元，占 2024 年度公司合 并报表中归属于上市公司普通股股东的净利润的比率为 43.63%。 二、公司履行的决策程序 （一）董事会会议的召开、审议和表决情况 2025 年 4 月 23 日，公司召开第十届董事会第十七次会议，以"赞 成票：9 票，反对票：0 票，弃权票：0 票"审议通过了《公司 2024 年度利润分配预案》。 本次利润分配预案已经公司第十届董事会第十七次会议和第十 届监事会第十四次会议审议通过，尚需提交公司 ...

山东省药用玻璃股份有限公司 关于计提 2024 年度激励基金的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为充分调动和发挥山东省药用玻璃股份有限公司分配激励机制 功能，增强董事、监事、高级管理人员以及公司业务骨干对实现公司 持续、健康发展的责任感、使命感，确保公司发展目标的实现，根据 《公司章程》、《山东省药用玻璃股份有限公司激励基金管理办法》， 拟定了公司计提 2024 年度激励基金的议案如下 一、计提激励基金的依据 《山东省药用玻璃股份有限公司激励基金管理办法》中规定： 1、若上年度净利润增长率在 6%以下，不提取激励基金； 2、若上年度净利润增长率达到 6%时，则按上年度净利润增长额 的 25%计算可提取的激励基金，即本年度可提取激励基金额=上年度 的净利润增长额×25%；本办法净利润定义为扣除非经常性损益前的 净利润和扣除非经常性损益后的净利润的低者； 3、提取的激励基金计入提取当年的成本费用； 证券代码：600529 证券简称：山东药玻 编号：2025-022 1 、 公 司 2024 年 度 实 现 ...

山东省药用玻璃股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhepa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台 7b- 监管平台 (http://acc 内部控制审计报告 中汇会审[2025] 5171号 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是山东药玻 公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于 情况的变化可能导致内部控制变得不恰当,或对控制政策和 ...

山东省药用玻璃股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 目 录 | | 页 次 | | --- | --- | | 一、审计报告 | 1-5 | | 二、财务报表 | 6-17 | | (一) 合并资产负债表 | 6-7 | | (二) 合并利润表 | 8 | | (三) 合并现金流量表 | 9 | | (四) 合并所有者权益变动表 | 10-11 | | (五) 母公司资产负债表 | 12-13 | | (六) 母公司利润表 | 14 | | (七) 母公司现金流量表 | 15 | | (八) 母公司所有者权益变动表 | 16-17 | 三、财务报表附注 18-117 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、 ...

中信证券股份有限公司 关于山东省药用玻璃股份有限公司 使用闲置募集资金购买理财产品的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为山东省 药用玻璃股份有限公司（以下简称"山东药玻"或"公司"）非公开发行 A 股 股票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所股票上市规 则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定， 对山东药玻使用闲置募集资金购买理财产品事项进行了核查，核查情况及核查意 见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准山东省药用玻璃股份有限公司非公开 发行股票的批复》（证监许可〔2022〕1852 号）核准，公司非公开发行 A 股股 票 68,646,366 股，每股发行价格为 27.19 元，共募集资金人民币 1,866,494,691.54 元，扣除不含税发行费用人民币 24,174,380.88 元后，公司募集资金净额为人民 币 1,842,320,310.66 元。募集资金已于 2022 年 11 月 14 日汇入公司开立的募集 ...

关于公司聘请2025年度财务及内部控制审计机构的事前认可意见 2025 年 4 月 25 日 中汇会计师事务所（特殊普通合伙）具备证券、期货相关业务审计从 业资格，具备为上市公司提供审计服务的经验和能力，在其他公司历年的 审计过程中，能够按照注册会计师独立审计准则实施审计工作，遵循独立、 客观、公正的执业准则。我们同意聘任中汇会计师事务所（特殊普通合伙） 为公司2025年度财务及内部控制审计机构，并将相关议案提交公司第十届 董事会第十七次会议审议和2024年年度股东大会审议。 山东省药用玻璃股份有限公司独立董事 独立董事：孙宗彬、顾维军、陈茂鑫 根据《公司法》《上市公司独立董事规则》等法律、法规和规范性文 件，以及《公司章程》等相关规定，我们对山东省药用玻璃股份有限公司 （以下简称"公司"）聘请2025年度财务及内部控制审计机构发表独立意 见如下： ...

山东省药用玻璃股份有限公司 独立董事 2024 年度述职报告（孙宗彬） 报告期内，作为山东药玻的独立董事，本着对公司和全体股东诚 信和勤勉的态度，以关注和维护全体股东特别是中、小股东的利益为 宗旨，恪尽职守，认真负责，严格履行了国家法律法规、《公司章程》、 《山东药玻独立董事管理办法》以及各专门委员会工作实施细则规定 的独立董事职责，为公司规范运作与科学决策提供了专业依据。现将 本人 2024 年度担任独立董事的履职情况报告如下： 一、基本情况 孙宗彬，男，1972 年 1 月出生，本科学历，2001 年毕业于山东 经济学院，历任山东海天会计师事务所副所长、北京兴华会计师事务 所山东分所副所长、中天运会计师事务所山东分所副所长，山东先达 农化股份有限公司独立董事。现任中一会计师事务所济南分所总经理、 亚星化学独立董事、山东药玻独立董事。报告期内任职期间未持有山 东药玻股份。 报告期内作为公司独立董事，本人未在公司担任除独立董事以外 的其他职务，与公司、公司的控股股东不存在可能妨碍本人进行独立 客观判断的关系，本人也没有从公司、公司控股股东及其关联方取得 额外的、未予披露的其他利益。本人任职符合《上市公司独立董 ...

Financial Performance - The company's operating revenue for 2024 reached CNY 5,125,270,640.68, representing a 2.87% increase compared to CNY 4,982,198,167.78 in 2023[21] - Net profit attributable to shareholders for 2024 was CNY 942,991,305.41, marking a 21.55% increase from CNY 775,802,014.62 in the previous year[21] - The net cash flow from operating activities for 2024 was CNY 1,165,050,367.90, an increase of 11.17% from CNY 1,047,982,969.39 in 2023[21] - The total assets at the end of 2024 amounted to CNY 10,140,009,365.84, an 8.81% increase from CNY 9,318,721,550.84 in 2023[21] - The company's net assets attributable to shareholders reached CNY 8,007,769,690.55 at the end of 2024, reflecting a 6.28% increase from CNY 7,534,508,778.17 in 2023[21] - Basic earnings per share for 2024 were CNY 1.42, a 21.37% increase compared to CNY 1.17 in 2023[22] - The weighted average return on equity for 2024 was 12.09%, up from 10.73% in 2023[22] Operational Efficiency - The company experienced a 16.83% reduction in customer complaint rates and a 33.08% increase in changeover efficiency due to the implementation of lean management practices[31] - The company reported a 57.4% reduction in failure rates, showcasing improvements in production stability and operational efficiency[31] - The company achieved ultra-low emissions standards for all kilns and transitioned to proactive pollution reduction measures, significantly lowering environmental costs per ton of glass[36][37] - The company has implemented a comprehensive safety management system, with over 6,100 employees participating in safety training programs in 2024[38] Product Development and Innovation - The introduction of an AI-powered inspection system in 2024 significantly enhanced product quality detection capabilities, improving detection efficiency and accuracy[32] - The company successfully developed new products such as medical synthetic polyisoprene gaskets and halogenated butyl rubber stoppers, which are expected to enhance profit margins and market competitiveness[34] - In 2024, the company applied for 49 patents and received authorization for 40 patents, including 4 invention patents, showcasing significant achievements in technological innovation[35] Market Position and Strategy - The company’s international market share for main products, including brown bottles and molded bottles, has increased, driven by quality and supply chain advantages[29] - The company is a leading player in the pharmaceutical glass industry, alongside major competitors such as Gerresheimer and Schott, which dominate the market share[48] - The company employs a direct sales and distribution model to leverage its brand and price advantages in the domestic market while actively expanding into international markets[56] Regulatory Environment - The National Medical Products Administration (NMPA) issued a notice on July 16, 2019, clarifying the association review and approval of raw materials and packaging materials related to drug formulations[41] - The revised Drug Administration Law implemented on December 1, 2019, mandates that the NMPA reviews chemical raw materials and related packaging materials together with drug formulations[41] - The NMPA's announcement on July 2019 established that drug formulation approvals indicate that associated raw materials have passed technical reviews, with registration status marked as "A"[43] Corporate Governance - The company is focused on maintaining strong governance and transparency in its operations[100] - The management team has a diverse background in various sectors, enhancing the company's strategic capabilities[100] - The company has maintained stable shareholding for key executives, with no significant changes reported[99] Environmental Responsibility - The company invested CNY 59.7 million in environmental protection during the reporting period[129] - The company has established a comprehensive waste management strategy, ensuring that all solid waste is legally disposed of and utilized[140] - The company has implemented a continuous monitoring system for waste gas emissions, ensuring real-time data reporting to environmental authorities[142] Employee Engagement and Welfare - The company has focused on employee welfare, providing benefits during holidays and health check-ups, which has positively impacted employee satisfaction and stability[38] - The company has implemented a training program aimed at improving employee skills and overall performance, focusing on quality enhancement and cost reduction[116] Risk Management - The company has established a comprehensive risk management system to enhance financial data analysis and fund usage supervision[126] - The company is addressing market risks by improving product quality and customer service to mitigate competition in the domestic market[92] Shareholder Relations - The company approved a cash dividend of CNY 411,440,750.06, which represents 43.63% of the net profit attributable to ordinary shareholders for the most recent fiscal year[121] - The cumulative cash dividend amount over the last three accounting years is CNY 842,104,437.10, with a cash dividend ratio of 108.10% based on the average net profit during that period[123]

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,242,455,243.50, a decrease of 1.97% compared to ¥1,267,462,044.57 in the same period last year[3] - Net profit attributable to shareholders was ¥223,629,434.88, reflecting a slight increase of 1.29% from ¥220,789,398.54 year-on-year[3] - Basic earnings per share rose to ¥0.34, up 3.03% from ¥0.33 in the same period last year[3] - Net profit for Q1 2025 was CNY 223,629,434.88, an increase of 1.3% compared to CNY 220,789,398.54 in Q1 2024[17] - The net profit attributable to the parent company's shareholders for the current period is CNY 223,629,434.88, compared to CNY 220,789,398.54 in the previous period, reflecting a slight increase[18] - The total comprehensive income for the current period is CNY 223,629,434.88, consistent with the net profit attributable to the parent company[18] Cash Flow - The net cash flow from operating activities decreased significantly by 69.43%, amounting to ¥90,533,209.57 compared to ¥296,176,607.65 in the previous year[3] - Cash flow from operating activities for the current period is CNY 90,533,209.57, a significant decrease from CNY 296,176,607.65 in the previous period[21] - Cash inflow from investment activities is CNY 1,598,445,580.50, compared to CNY 1,220,157,795.45 in the previous period, indicating a strong performance in this area[21] - The net cash flow from investment activities is CNY 10,032,671.59, a recovery from a negative CNY 426,192,878.57 in the previous period[22] - The net increase in cash and cash equivalents for the current period is CNY 104,408,670.45, contrasting with a decrease of CNY 124,950,594.87 in the previous period[22] - The ending balance of cash and cash equivalents is CNY 989,590,032.16, down from CNY 1,161,950,132.81 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,173,365,821.62, showing a slight increase of 0.33% from ¥10,140,009,365.84 at the end of the previous year[4] - Total current assets as of March 31, 2025, were CNY 6,054,844,132.51, slightly up from CNY 5,980,458,741.73 as of December 31, 2024[14] - Total non-current assets decreased to CNY 4,118,521,689.11 from CNY 4,159,550,624.11 as of December 31, 2024[14] - Total liabilities as of March 31, 2025, were CNY 1,943,079,956.55, down from CNY 2,132,239,675.29 as of December 31, 2024[15] - The company reported a decrease in accounts payable to CNY 776,475,750.05 from CNY 903,594,044.08[14] Shareholder Information - Shareholders' equity attributable to shareholders increased by 2.78%, reaching ¥8,230,285,865.07 compared to ¥8,007,769,690.55 at the end of the last year[4] - Shareholders' equity increased to CNY 8,230,285,865.07 as of March 31, 2025, compared to CNY 8,007,769,690.55 as of December 31, 2024[15] - The number of ordinary shareholders at the end of the reporting period was 70,488[6] Expenses and Gains - Total operating costs for Q1 2025 were CNY 982,600,179.31, down 2.1% from CNY 1,004,324,485.10 in Q1 2024[17] - Research and development expenses in Q1 2025 amounted to CNY 49,680,967.32, up 24.4% from CNY 39,921,990.72 in Q1 2024[17] - The company reported a total of ¥9,442,163.87 in non-recurring gains and losses for the period[5] - Investment income saw a significant increase of 104.13%, attributed to the maturity income from structured deposits[5] - The company experienced a 39.39% rise in financial expenses due to decreased interest income and exchange gains[5] Accounting Standards - The company has not reported any net profit from subsidiaries prior to consolidation for the current or previous periods[18] - The company is not applying new accounting standards or interpretations for the current reporting period[22]